Authors

Understand the Use of Panzyga for Immune-Related Disorders

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Dordaviprone: Safety, Efficacy, and Implications for Pharmacy Practice

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

Olympic Athlete Tabitha Peterson, PharmD, on Supporting Safe Performance in Sports

Olympic athlete Tabitha Peterson, PharmD, reveals how sports pharmacy helps athletes avoid antidoping risks, manage supplements safely, and stay competition-ready.

Implementing CDC’s Core Elements of Sepsis

The agency outlines key elements for building effective hospital sepsis programs.

ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk

New SYNCHRONIZE data signal broad metabolic and hepatic benefits.

Biosimilar Adoption: The Pharmacist's Role in Formulary Decisions, Patient Counseling, and Safe Use

Biosimilars lower biologic costs and widen access.

Pharmacy Logistics, Emerging Safety and Efficacy Data, and Future Directions for Menin Inhibitors in Acute Leukemias

Targeted menin inhibitors offer new hope for patients with difficult-to-treat acute leukemias.

The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Rethinking Escalation in Relapsing MS

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Patricia K. Coyle, MD, a Director at the MS Center at Stony Brook Medicine, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking escalation strategies in relapsing MS.

Pharmacists Can Intervene in Commonly Overlooked Medication Errors

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Flushing the Old Away: Transitioning From Heparin to Saline for Implanted Port Maintenance

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

More Options, More Questions: How Pharmacists Are Managing EGFR-Positive Non-Small Cell Lung Cancer

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

Medication Management and Supply Chain Still Underwater: Challenges and Future Trends in Health Care

From Inpatient to Outpatient: A Pharmacy-Led Evolution in Transplant Care

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

How Medication Stigma and Bias Can Impact Patient Recovery

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how medication stigma and bias can impact patient recovery.

Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.

Pharmacists Leading the Treatment of Multiple Myeloma: Precision Therapy and Collaborative Oncology Care

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

For Optimal Bioavailability, Administer Dronedarone With a Complete Meal

Bioavailability of dronedarone is markedly increased when administered with food. To maximize absorption, patients should take dronedarone with a complete meal (ideally >500 calories).

ADA 2026: Key Challenges in Optimizing Cardio-Renal Risk in Diabetes

Pharmacy Times interviews Tracey Taveira, Pharm.D., CDOE, CVDOE, on the key challenges she discovered in optimizing cardio-renal risk in diabetes that she presented in ADA 2026.

The Future of GLP-1 Therapies: Hype, Evidence, and the Expanding Role of Pharmacists

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.

Pharmacist-Led BiTE Program at a Community Cancer Center

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

Op-Ed: FTC Adds Fuel to the Fire for PBMs. Will Congress Deliver Real Reform?

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board for a different approach.

Research Underscores the Critical Role of Pharmacists in Managing Stiff Person Syndrome

Stiff Person Syndrome has unique complexities, necessitating the role of pharmacists in managing its symptoms and treatment options.

Daratumumab Plus VRd Continues to Demonstrate Durable Benefits in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.

Real-World Evidence Helps Accelerate Formulary Decisions for Biologics